Early Experiences of a Minimal Invasive Intra-Prostatic Implant, Prostatic Urethral Lift for Benign Prostatic Hyperplasia Treatment in Korea
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: As a minimal invasive device for benign prostatic hyperplasia (BPH) treatment, prostatic urethral lift (PUL) is widely accepted worldwide but not widely used in Korea. We investigated the one-year results of for patients with BPH in Korea.Materials and Methods: From April 2017 to June 2018, 42 patients with BPH were treated with PUL under local anesthesia with sedation. International Prostate Symptom Score (IPSS) and maximum urinary flow rate and post-void residual (PVR) were evaluated preoperatively and 1, 3, 6, and 12 months later.Results: Mean age was 69.57±8.58 years old, and mean prostatic volume was 37.17±12.19 cc. Preoperative total IPSS and quality of life (QOL) were 19.94±7.81 and 3.69±1.30, respectively. Total IPSS improved to 11.26±7.22 (p<0.001), and QOL was 2.42±1.43 (p=0.01) after one month. Patients showed no evidence of inflammation related to the implants. IPSS and QOL were somewhat worse after 3 months but were better than baseline at 6 and 12 months. Preoperative maximum flow rate (Qmax) was 9.71±5.45 ml/sec, and one month after surgery, it had improved to 12.63±7.33 (p=0.01); it remained good at 3, 6, and 12 months (12.63±7.38, 12.45±7.39, 14.73±9.67). PVR was not significant at any points postoperative (80.61±67.91 to 43.95±8.19, p=0.119). No patient reported retrograde ejaculation, erectile dysfunction or urinary tract infection.Conclusions: We evaluated the one-year efficacy of PUL for BPH treatment in Korea, and found significant improvement of IPSS, QOL and Qmax. It is expected that not only the improvement of voiding symptom but also the preservation of sexual function with a low risk of adverse events.
Abstract
Purpose: As a minimal invasive device for benign prostatic hyperplasia (BPH) treatment, prostatic urethral lift (PUL) is widely accepted worldwide but not widely used in Korea. We investigated the one-year results of for patients with BPH in Korea.Materials and Methods: From April 2017 to June 2018, 42 patients with BPH were treated with PUL under local anesthesia with sedation. International Prostate Symptom Score (IPSS) and maximum urinary flow rate and post-void residual (PVR) were evaluated preoperatively and 1, 3, 6, and 12 months later.Results: Mean age was 69.57±8.58 years old, and mean prostatic volume was 37.17±12.19 cc. Preoperative total IPSS and quality of life (QOL) were 19.94±7.81 and 3.69±1.30, respectively. Total IPSS improved to 11.26±7.22 (p<0.001), and QOL was 2.42±1.43 (p=0.01) after one month. Patients showed no evidence of inflammation related to the implants. IPSS and QOL were somewhat worse after 3 months but were better than baseline at 6 and 12 months. Preoperative maximum flow rate (Qmax) was 9.71±5.45 ml/sec, and one month after surgery, it had improved to 12.63±7.33 (p=0.01); it remained good at 3, 6, and 12 months (12.63±7.38, 12.45±7.39, 14.73±9.67). PVR was not significant at any points postoperative (80.61±67.91 to 43.95±8.19, p=0.119). No patient reported retrograde ejaculation, erectile dysfunction or urinary tract infection.Conclusions: We evaluated the one-year efficacy of PUL for BPH treatment in Korea, and found significant improvement of IPSS, QOL and Qmax. It is expected that not only the improvement of voiding symptom but also the preservation of sexual function with a low risk of adverse events.
참고문헌 (25)
- Verhamme KM, "Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia : the Triumph project", Eur Urol, 44, pp.539~545 (2003)
- Roehrborn CG, "Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia : achievements and limitations", Rev Urol, 10, pp.14~25 (2008)
- 박형근, "한국 노령층의 전립선비대증 유병률: 지역기반 연구", Investigative and Clinical Urology, 50(9), pp.843~847 (2009), 대한비뇨의학회
- AUA Practice Guidelines Committee, "AUA guideline on management of benign prostatic hyperplasia, Chapter 1:diagnosis and treatment recommendations", J Urol, 170, pp.530~547 (2003)
- Nickel JC, "The American Urological Association 2003guideline on management of benign prostatic hyperplasia : a Canadian opinion", Can J Urol, 11, pp.2186~2193 (2004)
- McVary KT, "Update on AUA guideline on the management of benign prostatic hyperplasia", J Urol, 185, pp.1793~1803 (2011)
- Bouza C, "Systematic review and meta-analysis of transurethral needle ablation in symptomatic benign prostatic hyperplasia", BMC Urol, 6, pp.14~ (2006)
- Andersen M, "Microwave thermotherapy for benign prostatic hyperplasia. A survey of a Cochrane review", Ugeskr Laeger, 171, pp.2281~2284 (2009)
- Chin PT, "Prostatic urethral lift : two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia", Urology, 79, pp.5~11 (2012)
- McNicholas TA, "Minimally invasive prostatic urethral lift : surgical technique and multinational experience", Eur Urol, 64, pp.292~299 (2013)
- Jones P, "Urolift : a new chapter in benign prostate hyperplasia(BPH)therapy", Ann Transl Med, 4, pp.116~ (2016)
- Jones P, "Medium-term outcomes of urolift(minimum 12 months follow-up) : evidence from a systematic review", Urology, 97, pp.20~24 (2016)
- "Korean Statistical Information Service" (2014)[URL]
- 이영주, "Nationwide incidence and treatment pattern of benign prostatic hyperplasia in Korea", Investigative and Clinical Urology, 57(6), pp.424~430 (2016), 대한비뇨의학회[DOI]
- Barrack ER, "Subcellular distribution of androgen receptors in human normal, benign hyperplastic, and malignant prostatic tissues : characterization of nuclear saltresistant receptors", Cancer Res, 43, pp.1107~1116 (1983)
- Martin DJ, "Enlarging the scope of managing benign prostatic hyperplasia : addressing sexual function and quality of life", Int J Clin Pract, 59, pp.579~590 (2005)
- Ulchaker JC, "Cost-effectiveness analysis of six therapies for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia", Clinicoecon Outcomes Res, 10, pp.29~43 (2017)
- Roehrborn CG, "The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study", J Urol, 190, pp.2161~2167 (2013)
- Cantwell AL, "Multicentre prospective crossover study of the ‘prostatic urethral lift’ for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia", BJU Int, 113, pp.615~622 (2014)
- Shore N, "Prospective multi-center study elucidating patient experience after prostatic urethral lift", Can J Urol, 21, pp.7094~7101 (2014)
- Rukstalis DB, "Prostatic urethral lift: a novel approach for managing symptomatic BPH in the aging man", Can J Urol, 22(Suppl 1), pp.67~74 (2015)
- Sønksen J, "Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate : 12-month results from the BPH6 study", Eur Urol, 68, pp.643~652 (2015)
- Rassweiler J, "Complications of transurethral resection of the prostate(TURP)--incidence, management, and prevention", Eur Urol, 50, pp.969~979 (2006)
- Alloussi SH, "Ejaculation-preserving transurethral resection of prostate and bladder neck : short-and long-term results of a new innovative resection technique", J Endourol, 28, pp.84~89 (2014)
- Schoenthaler M, "Combined prostatic urethral lift and remodeling of the prostate and bladder neck : a modified transurethral approach in the treatment of symptomatic lower urinary tract obstruction", World J Urol, 36, pp.1111~1116 (2018)